Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2016

Open Access 01-12-2016 | Primary research

Robo3A and Robo3B expression is regulated via alternative promoters and mRNA stability

Authors: Anke Ruedel, Mandy Schott, Thomas Schubert, Anja Katrin Bosserhoff

Published in: Cancer Cell International | Issue 1/2016

Login to get access

Abstract

Background

The transmembrane receptor family Roundabout (Robo) was described to have an essential role in the developing nervous system. Recent studies demonstrated that Robo3 shows an altered expression in rheumatoid arthritis as well as in melanoma.

Context and purpose of the study

Until today no detailed studies of the two Robo3 isoforms (Robo3A and Robo3B) and their roles in rheumatoid arthritis synovial fibroblasts, respectively malignant melanoma are available. To get a better understanding regarding the role of Robo3A and Robo3B in the molecular process of rheumatoid arthritis and melanoma the exact characterization of expression and regulation is object of this study.

Results

mRNA and protein expression of the transcriptional variants were analyzed by quantitative RT-PCR respectively western blotting and revealed particularly enhanced expression of Robo3B in rheumatoid arthritis and melanoma. Promoter assays and inhibitor studies also disclosed that there is apparently a cell- and isoform-specific regulation of the Robo3 expression. Finally, dissimilar mRNA stabilities of Robo3A and Robo3B are identified as decisive posttranscriptional gene expression control.

Conclusion

In summary, this study supported an isotype specific role of Robo3B in disease hinting to different functional roles of each isoform.
Literature
1.
Sabatier C, Plump AS, Le M, et al. The divergent Robo family protein rig-1/Robo3 is a negative regulator of slit responsiveness required for midline crossing by commissural axons. Cell. 2004;117(2):157–69.CrossRefPubMed
2.
3.
Schubert T, Denk AE, Ruedel A, et al. Fragments of SLIT3 inhibit cellular migration. Int J Mol Med. 2012;30(5):1133–7.PubMed
4.
Dickinson RE, Hryhorskyj L, Tremewan H, et al. Involvement of the SLIT/ROBO pathway in follicle development in the fetal ovary. Reproduction. 2010;139(2):395–407.CrossRefPubMed
5.
Ypsilanti AR, Zagar Y, Chedotal A. Moving away from the midline: new developments for slit and Robo. Development. 2010;137(12):1939–52.CrossRefPubMed
6.
Zelina P, Blockus H, Zagar Y, et al. Signaling switch of the axon guidance receptor Robo3 during vertebrate evolution. Neuron. 2014;84(6):1258–72.CrossRefPubMed
7.
Camurri L, Mambetisaeva E, Davies D, Parnavelas J, Sundaresan V, Andrews W. Evidence for the existence of two Robo3 isoforms with divergent biochemical properties. Mol Cell Neurosci. 2005;30(4):485–93.CrossRefPubMed
8.
Challa AK, McWhorter ML, Wang C, Seeger MA, Beattie CE. Robo3 isoforms have distinct roles during zebrafish development. Mech Dev. 2005;122(10):1073–86.CrossRefPubMed
9.
Denk AE, Kaufmann S, Stark K, et al. Slit3 inhibits Robo3-induced invasion of synovial fibroblasts in rheumatoid arthritis. Arthr Res Ther. 2010;12(2):R45.CrossRef
10.
Denk AE, Braig S, Schubert T, Bosserhoff AK. Slit3 inhibits activator protein 1-mediated migration of malignant melanoma cells. Int J Mol Med. 2011;28(5):721–6.PubMed
11.
Ruedel A, Dietrich P, Schubert T, Hofmeister S, Hellerbrand C, Bosserhoff AK. Expression and function of microRNA-188-5p in activated rheumatoid arthritis synovial fibroblasts. Int J Clin Exp Pathol. 2015;8(5):4953–62.PubMedPubMedCentral
12.
Miller LE, Jüsten HP, Schölmerich J, Straub RH. The loss of sympathetic nerve fibers in the synovial tissue of patients with rheumatoid arthritis is accompanied by increased norepinephrine release from synovial macrophages. FASEB J. 2000;14(13):2097–107.CrossRefPubMed
13.
Ruedel A, Hofmeister S, Bosserhoff AK. Development of a model system to analyze chondrogenic differentiation of mesenchymal stem cells. Int J Clin Exp Pathol. 2013;6(12):3042–8.PubMedPubMedCentral
14.
Bosserhoff AK, Hofmeister S, Ruedel A, Schubert T. DCC is expressed in a CD166-positive subpopulation of chondrocytes in human osteoarthritic cartilage and modulates CRE activity. Int J Clin Exp Pathol. 2014;7(5):1947–56.PubMedPubMedCentral
15.
Shim J, Karin M. The control of mRNA stability in response to extracellular stimuli. Mol Cells. 2002;14(3):323–31.PubMed
16.
Gara RK, Kumari S, Ganju A, Yallapu MM, Jaggi M, Chauhan SC. Slit/Robo pathway: a promising therapeutic target for cancer. Drug Discov Today. 2015;20(1):156–64.CrossRefPubMed
17.
Han S, Cao C, Tang T, et al. ROBO3 promotes growth and metastasis of pancreatic carcinoma. Cancer Lett. 2015;366(1):61–70.CrossRefPubMed
18.
Narayan G, Goparaju C, Arias-Pulido H, et al. Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol Cancer. 2006;5:16.CrossRefPubMedPubMedCentral
19.
Kuphal S, Bosserhoff AK. Influence of the cytoplasmic domain of E-cadherin on endogenous N-cadherin expression in malignant melanoma. Oncogene. 2006;25(2):248–59.PubMed
20.
Jen JC, Chan WM, Bosley TM, et al. Mutations in a human ROBO gene disrupt hindbrain axon pathway crossing and morphogenesis. Science. 2004;304(5676):1509–13.CrossRefPubMedPubMedCentral
21.
Singer GA, Wu J, Yan P, Plass C, Huang TH, Davuluri RV. Genome-wide analysis of alternative promoters of human genes using a custom promoter tiling array. BMC Genom. 2008;9:349.CrossRef
22.
Landry JR, Mager DL, Wilhelm BT. Complex controls: the role of alternative promoters in mammalian genomes. Trends Genetics TIG. 2003;19(11):640–8.CrossRefPubMed
23.
Nural HF, Todd Farmer W, Mastick GS. The Slit receptor Robo1 is predominantly expressed via the Dutt1 alternative promoter in pioneer neurons in the embryonic mouse brain and spinal cord. Gene Expr Patterns GEP. 2007;7(8):837–45.CrossRefPubMed
24.
Thalhamer T, McGrath MA, Harnett MM. MAPKs and their relevance to arthritis and inflammation. Rheumatol (Oxford). 2008;47(4):409–14.CrossRef
25.
Kuphal S, Bosserhoff A. Recent progress in understanding the pathology of malignant melanoma. J Pathol. 2009;219(4):400–9.CrossRefPubMed
26.
Shelledy L, Roman D. Vemurafenib: first-in-class BRAF-mutated inhibitor for the treatment of unresectable or metastatic melanoma. J Adv Pract Oncol. 2015;6(4):361–5.PubMedPubMedCentral
27.
Rajagopalan S, Nicolas E, Vivancos V, Berger J, Dickson BJ. Crossing the midline: roles and regulation of Robo receptors. Neuron. 2000;28(3):767–77.CrossRefPubMed
28.
Simpson JH, Bland KS, Fetter RD, Goodman CS. Short-range and long-range guidance by Slit and its Robo receptors: a combinatorial code of Robo receptors controls lateral position. Cell. 2000;103(7):1019–32.CrossRefPubMed
29.
Chen CY, Shyu AB. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci. 1995;20(11):465–70.CrossRefPubMed
30.
Schiavi SC, Belasco JG, Greenberg ME. Regulation of proto-oncogene mRNA stability. Biochim Biophys Acta. 1992;1114(2–3):95–106.PubMed
31.
Chen CY, Gherzi R, Andersen JS, et al. Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation. Genes Dev. 2000;14(10):1236–48.PubMedPubMedCentral
Metadata
Title
Robo3A and Robo3B expression is regulated via alternative promoters and mRNA stability
Authors
Anke Ruedel
Mandy Schott
Thomas Schubert
Anja Katrin Bosserhoff
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2016
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-016-0347-9

Other articles of this Issue 1/2016

Cancer Cell International 1/2016 Go to the issue

Primary research

Positive effect of HPV status on prognostic value of blood lymphocyte-to-monocyte ratio in advanced cervical carcinoma

Primary research

Temozolomide promotes genomic and phenotypic changes in glioblastoma cells

Primary research

Selected polyphenols potentiate the apoptotic efficacy of glycolytic inhibitors in human acute myeloid leukemia cell lines. Regulation by protein kinase activities

Primary research

Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative

Primary research

miRNA-135a promotes hepatocellular carcinoma cell migration and invasion by targeting forkhead box O1

Primary research

Weight loss reduces basal-like breast cancer through kinome reprogramming
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits